Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Qizhi Zhai
Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
Related publications
Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Icotinib Is as Efficacious as Gefitinib for Brain Metastasis of EGFR Mutated Non-Small-Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Korean Journal of Internal Medicine
Internal Medicine
Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy
Research in Oncology
Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
